ClinicalTrials.gg

Stroke clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 8,269 studies for Stroke across more than 10 countries. 2,062 are recruiting or about to start. 5,645 of them are mainly about Stroke (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 10 narrower conditions too, such as Ischemic Stroke: 10,307 studies, 2,860 open.

ClinicalTrials.gov finds 11,396 studies for Stroke. How that becomes 8,268 here

This page counts the studies the registry files under Stroke, and those it files under no condition that list Strokethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 11,396Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,034Filed under a narrower condition, counted on its own pageIschemic Stroke 1,744 · Cerebral Infarction 90 · Hemorrhagic Stroke 43 · CADASIL 28 · Brain Stem Infarctions 24 · Brain Infarction 15 · 4 more
  3. −282List Stroke as a condition, but the registry did not file them under itMost often written as “Stroke Sequelae” (17), “Chronic Stroke” (16), and “Heat Stroke” (15). The registry filed 1 of them under no condition at all, and the others under other conditions only, most often Atrial Fibrillation (23) and Brain Injuries (22).
  4. −812Match it another way647 name it in the title, 152 in a keyword, and 13 by a synonym or other text the search reads.
  5. 8,268The count on this page411 of them list Stroke in their own words; the registry filed them under no condition.

Status

Completed
4,255
Recruiting
1,419
Status unknown
1,052
Not yet recruiting
540
Terminated
377
Active, not recruiting
300

Phase

Phase 2
563
Phase 3
422
Phase 1
295
Phase 4
239
Early Phase 1
61

Where

United States
1,995
China
611
France
543
Turkey
484
Canada
444
Taiwan
394

Who develops what

Add Stroke to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 19 programs from 15 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Eli Lilly, Jiangsu HengRui Medicine and Regeneron Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Drug VehicleRecent, limited
Evidence
  • NCT05691244 · Pharmazz, Inc. · Phase 3 · live · comparator · “Drug: Normal Saline” · registered Jan 2023
  • NCT04047563 · Pharmazz, Inc. · Phase 3 · comparator · “Normal Saline along with standard treatment” · registered Aug 2019
  • NCT04046484 · Pharmazz, Inc. · Phase 2 · comparator · “Normal Saline along with standard treatment” · registered Jul 2019
—11 study
apixabanRecent, limited
Evidence
  • NCT07626411 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Apixaban” · registered May 2026
  • NCT07175428 · Regeneron Pharmaceuticals · Phase 2 · live · comparator · “Apixaban” · registered Sep 2025
Bristol-Myers Squibb59% of its industry studiesUS: off-patent, 1 generic marketedEU: off-patent, 1 generic authorized12 studies
TacrolimusRecent, limited
Evidence
  • NCT07709845 · Clarion Cells, Inc. · Phase 2 · live · background · “Tacrolimus” · registered Jul 2026
Astellas Pharma Inc62% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 1 generic authorized11 study

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
cenvacibart☆ Track2 live phase-3 studies: NCT07626411, NCT07876492Regeneron Pharmaceuticals

The 1 in phase 3 with the nearest primary completion, of 19 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 9 Feb 2027 est.cenvacibart, amrecibart · Regeneron Pharmaceuticals · Phase 2 registry mapping onlyvs apixabanNCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — primary endpoint: Incidence of any bleeding · 1,200 enrolled
  • Apr 2027 est.emoxypine succinate · Pharmasoft · Phase 4 named, not the main aimvs GlycineNCT07575984 Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke — primary endpoint: Infarct Volume at Visit 2 (Day 11) · 120 enrolled
  • Jun 2027 est.BB-031 · Basking Biosciences, Inc. · Phase 2 named, not the main aimNCT06226805 Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) — primary endpoint: Symptomatic Intracranial Hemorrhage (sICH) · 228 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Stroke studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Thrombolytics 13 open · Factor Xa inhibitors 12 open · Statins 4 open · P2Y12 inhibitors 3 open · GLP-1 receptor agonists 3 open

Coming up

651studies finish main data collection within a year16 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger. 77 (5%) take children under 18. 3 (<1%) are for women only and 2 (<1%) for men only; 196 (14%) take healthy volunteers.

Recruiting studies that take each age, of 1,418
AgeWomenMen
1058 (4%)57 (4%)
18991 (70%)989 (70%)
301,159 (82%)1,156 (82%)
401,270 (90%)1,268 (89%)
501,361 (96%)1,361 (96%)
651,347 (95%)1,345 (95%)
751,236 (87%)1,234 (87%)
85922 (65%)920 (65%)

Across all 8,268 studies, recruiting or not: 18% stop at 75 or younger and 8% at 65; 8% take children; <1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Stroke studies take

Of 132 phase 2 interventional studies under Stroke, half reached primary completion within 40 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 120 mo7–38 · 97 studies9 mo4–14 · 26 studies29 mo11–45 · 71 studies
Phase 1/239 mo22–57 · 28 studies——
Phase 240 mo24–60 · 132 studies—43 mo24–60 · 112 studies
Phase 2/333 mo30–77 · 27 studies——
Phase 344 mo27–68 · 129 studies40 mo26–58 · 37 studies44 mo27–71 · 92 studies
Phase 457 mo29–95 · 90 studies—57 mo29–95 · 84 studies
Interventional, no phase23 mo10–46 · 3,261 studies24 mo11–43 · 144 studies23 mo10–46 · 3,117 studies
Observational40 mo18–85 · 899 studies33 mo24–58 · 62 studies41 mo18–92 · 837 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 17, 2026.

Started recruiting15

Show 10 more

Stopped1

Newly registered71

Show 45 more

and 21 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 8,269. Browse all 8,269 → or search them.